HEOR

News

NICE backs Alnylam's Amvuttra for rare form of amyloidosis

Alnylam's gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available

News

Female doctor with the stethoscope holding heart

NICE says statins should be used more widely in NHS

Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.

News

x-ray image of human head with brain and electric pulses

ICER says lecanemab data in Alzheimer's "inconclusive"

One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<

News

NICE expands breast cancer patient population eligible for E...

AstraZeneca and Daiichi Sankyo's Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available

News

NICE backs use of Boehringer's Ofev in IPF from diagnosis

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim's Ofev, following new guidance from health technology assess

Partner Content